Related Experiment Video

Updated: Jun 25, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K

Unveiling FDA-approved Drugs and Formulations in the Management of Bladder Cancer: A Review

Keshav Bansal1, Neeraj Chaudhary1, Hemant Bhati1

  • 1Institute of Pharmaceutical Research, GLA University, Mathura-281406, Uttar Pradesh, India.

Current Pharmaceutical Biotechnology
|May 27, 2024
PubMed

Insights

This review summarizes FDA-approved and investigational drugs for bladder cancer treatment, covering their mechanisms, pharmacokinetics, and novel formulations. It serves as a reference for scientists developing new bladder cancer therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Urological cancers, particularly bladder cancer, represent a significant global health challenge due to their aggressive and heterogeneous nature.
  • Existing treatments for solid tumors face limitations, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

  • To provide a comprehensive summary of U.S. Food and Drug Administration (FDA)-approved and investigational drugs for bladder cancer prevention and treatment.
  • To consolidate information on drug protocols, pharmacokinetics, mechanisms of action, and marketed products for bladder cancer therapeutics.

Main Methods:

  • Literature review of FDA-approved drugs for bladder cancer.
  • Inclusion of drugs currently in clinical trials or under regulatory review.
  • Compilation of data on drug formulations, pharmacokinetics, and mechanisms of action.

Main Results:

  • Detailed listing of FDA-approved bladder cancer drugs, including their dosage, status, pharmacokinetics, and mechanisms.
  • Emphasis on novel drug preparations currently undergoing clinical trials or awaiting approval.

Conclusions:

  • This review offers a consolidated resource for researchers and scientists engaged in the formulation development of bladder cancer drugs.
  • It highlights the current landscape and future directions in bladder cancer pharmacotherapy.
Keywords:
FDAUrological cancerbladder cancerclinical trials.solid tumorstargeted drugs

More Related Videos

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

19.3K
Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors05:19

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

10.3K

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
160